FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308952102> ?p ?o ?g. }

• W4308952102 endingPage "634" @default.
• W4308952102 startingPage "627" @default.
• W4308952102 abstract "The prognosis of patients with advanced gastrointestinal stromal tumor (GIST) has improved greatly after the introduction of imatinib. However, primary or secondary resistance to imatinib occurs in the majority of patients. Sunitinib is the standard second line treatment in exon-9 mutated GIST. We compared the clinical outcomes of sunitinib with imatinib dose escalation in patients with progressive advanced non-KIT exon 9 mutated GIST after failure of first line imatinib. A retrospective study was performed, retrieving data from a real-life database (Dutch GIST Registry) including patients with GIST treated with sunitinib or imatinib dose escalation after failure on first line imatinib 400 mg daily. Primary outcome measures were progression free survival (PFS) and overall survival (OS). In total, 110 patients were included, 72 (65.5%) patients were treated with sunitinib (group A) and 38 (34.5%) received an imatinib dose escalation (group B). Important prognostic features at baseline, such as tumor size, stage at diagnosis, mitotic count and localization were equally distributed in both groups. No significant difference (p = 0.88) between median PFS in group A [8.7 months (95% CI 5.6–11.3)] and group B [5.6 months, (95% CI 2.6–8.7)] was observed. Moreover, the OS was similar between group A and group B; 63.2 months and 63.4 months, respectively. This study represents a proper sample size cohort containing detailed data on mutational status of patients with advanced GIST. We illustrated that imatinib dose escalation could serve as a good alternative for sunitinib as second-line treatment in patients with a non-KIT exon 9 mutation." @default.
• W4308952102 created "2022-11-20" @default.
• W4308952102 creator A5018539395 @default.
• W4308952102 creator A5021911321 @default.
• W4308952102 creator A5037532883 @default.
• W4308952102 creator A5046503436 @default.
• W4308952102 creator A5047066048 @default.
• W4308952102 creator A5051744290 @default.
• W4308952102 creator A5066058445 @default.
• W4308952102 creator A5071462352 @default.
• W4308952102 creator A5076740454 @default.
• W4308952102 creator A5084671376 @default.
• W4308952102 date "2022-11-01" @default.
• W4308952102 modified "2023-10-01" @default.
• W4308952102 title "Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients" @default.
• W4308952102 cites W1970041112 @default.
• W4308952102 cites W2030035221 @default.
• W4308952102 cites W2040381070 @default.
• W4308952102 cites W2129931005 @default.
• W4308952102 cites W2139511378 @default.
• W4308952102 cites W2140626630 @default.
• W4308952102 cites W2143295396 @default.
• W4308952102 cites W2146306052 @default.
• W4308952102 cites W2159360580 @default.
• W4308952102 cites W2169363650 @default.
• W4308952102 cites W2171620774 @default.
• W4308952102 cites W2178731684 @default.
• W4308952102 cites W2601222128 @default.
• W4308952102 cites W2605154227 @default.
• W4308952102 cites W2782077264 @default.
• W4308952102 cites W2898170902 @default.
• W4308952102 cites W3037595396 @default.
• W4308952102 cites W3043812591 @default.
• W4308952102 cites W4238208852 @default.
• W4308952102 cites W772589830 @default.
• W4308952102 doi "https://doi.org/10.1007/s11523-022-00926-6" @default.
• W4308952102 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36374447" @default.
• W4308952102 hasPublicationYear "2022" @default.
• W4308952102 type Work @default.
• W4308952102 citedByCount "1" @default.
• W4308952102 countsByYear W43089521022023 @default.
• W4308952102 crossrefType "journal-article" @default.
• W4308952102 hasAuthorship W4308952102A5018539395 @default.
• W4308952102 hasAuthorship W4308952102A5021911321 @default.
• W4308952102 hasAuthorship W4308952102A5037532883 @default.
• W4308952102 hasAuthorship W4308952102A5046503436 @default.
• W4308952102 hasAuthorship W4308952102A5047066048 @default.
• W4308952102 hasAuthorship W4308952102A5051744290 @default.
• W4308952102 hasAuthorship W4308952102A5066058445 @default.
• W4308952102 hasAuthorship W4308952102A5071462352 @default.
• W4308952102 hasAuthorship W4308952102A5076740454 @default.
• W4308952102 hasAuthorship W4308952102A5084671376 @default.
• W4308952102 hasBestOaLocation W43089521021 @default.
• W4308952102 hasConcept C121608353 @default.
• W4308952102 hasConcept C126322002 @default.
• W4308952102 hasConcept C143998085 @default.
• W4308952102 hasConcept C167135981 @default.
• W4308952102 hasConcept C16930146 @default.
• W4308952102 hasConcept C2775922572 @default.
• W4308952102 hasConcept C2777007597 @default.
• W4308952102 hasConcept C2777583451 @default.
• W4308952102 hasConcept C2778729363 @default.
• W4308952102 hasConcept C2779490328 @default.
• W4308952102 hasConcept C3019892230 @default.
• W4308952102 hasConcept C71924100 @default.
• W4308952102 hasConcept C72563966 @default.
• W4308952102 hasConcept C90924648 @default.
• W4308952102 hasConceptScore W4308952102C121608353 @default.
• W4308952102 hasConceptScore W4308952102C126322002 @default.
• W4308952102 hasConceptScore W4308952102C143998085 @default.
• W4308952102 hasConceptScore W4308952102C167135981 @default.
• W4308952102 hasConceptScore W4308952102C16930146 @default.
• W4308952102 hasConceptScore W4308952102C2775922572 @default.
• W4308952102 hasConceptScore W4308952102C2777007597 @default.
• W4308952102 hasConceptScore W4308952102C2777583451 @default.
• W4308952102 hasConceptScore W4308952102C2778729363 @default.
• W4308952102 hasConceptScore W4308952102C2779490328 @default.
• W4308952102 hasConceptScore W4308952102C3019892230 @default.
• W4308952102 hasConceptScore W4308952102C71924100 @default.
• W4308952102 hasConceptScore W4308952102C72563966 @default.
• W4308952102 hasConceptScore W4308952102C90924648 @default.
• W4308952102 hasFunder F4320307771 @default.
• W4308952102 hasFunder F4320307778 @default.
• W4308952102 hasFunder F4320316900 @default.
• W4308952102 hasFunder F4320333645 @default.
• W4308952102 hasIssue "6" @default.
• W4308952102 hasLocation W43089521021 @default.
• W4308952102 hasLocation W43089521022 @default.
• W4308952102 hasLocation W43089521023 @default.
• W4308952102 hasLocation W43089521024 @default.
• W4308952102 hasLocation W43089521025 @default.
• W4308952102 hasLocation W43089521026 @default.
• W4308952102 hasLocation W43089521027 @default.
• W4308952102 hasLocation W43089521028 @default.
• W4308952102 hasLocation W43089521029 @default.
• W4308952102 hasOpenAccess W4308952102 @default.
• W4308952102 hasPrimaryLocation W43089521021 @default.
• W4308952102 hasRelatedWork W1559702962 @default.

• next